US FDA approves ozanimod for the treatment of multiple sclerosis

Ozanimod, an oral sphingosine-1-phosphate (S1P) receptor modulator, has been approved for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

SPS commentary:

An application seeking approval of ozanimod in the EU was filed in March 2019; final approval is awaited.


Biospace Inc.